China, Nov. 16 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Trastuzumab rezetecan combined with adebrelimab in the treatment of second-line and beyond HER2-positive advanced urothelial carcinoma: a phase II clinical study'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600136750
Registration Time: 2026/11/15
Type: Interventional study
Primary Sponsor: Jiangsu Cancer Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=331894
Published by HT Digital Content Services with permission from Health Daily Digest....